Decreased Th1-type inflammatory cytokine expression in the skin is associated with persisting symptoms after treatment of erythema migrans

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Sjöwall, Johanna ^a   Fryland, Linda ^a   Nordberg, Marika ^a,d   Sjögren, Florence ^a   Garpmo, Ulf ^b   Jansson, Christian ^d   Carlsson, Sten Anders ^d   Bergström, Sven ^c   Ernerudh, Jan ^a   Nyman, Dag ^d   Forsberg, Pia ^a   Ekerfelt, Christina ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KALMAR COUNTY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d Åland Islands ^*  (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BACTERIAL DNA; BACTERIUM ANTIBODY; CYTOKINE; DOXYCYCLINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 4; INTERLEUKIN 12;

ADULT; AGED; AMPLICON; ARTHRALGIA; ARTICLE; BACKACHE; BORRELIA AFZELII; BORRELIA BURGDORFERI; BORRELIA GARINII; CONTROLLED STUDY; CYTOKINE RESPONSE; ERYTHEMA CHRONICUM MIGRANS; FATIGUE; FEMALE; FINLAND; FOLLOW UP; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; HYPESTHESIA; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LYME DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SKIN BIOPSY; SPECIES DISTRIBUTION; TH1 CELL; TICK BITE; BLOOD; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; MIDDLE AGED; SKIN;

BORRELIA AFZELII; BORRELIA BURGDORFERI; BORRELIA GARINII;

ADULT; AGED; AGED, 80 AND OVER; BORRELIA BURGDORFERI; CYTOKINES; ERYTHEMA CHRONICUM MIGRANS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-4; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SKIN; YOUNG ADULT;

EID: 79953667657     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018220     Document Type: Article

References (43)

1. Salazar JC, Pope CD, Sellati TJ, Feder HM Jr, Kiely TG, et al. (2003) Coevolution of markers of innate and adaptive immunity in skin and peripheral blood of patients with erythema migrans. J Immunol 171: 2660-2670.
2. Berglund J, Eitrem R, Ornstein K, Lindberg A, Ringer A, et al. (1995) An epidemiologic study of Lyme disease in southern Sweden. N Engl J Med 333: 1319-1327.
3. Stanek G, Strle F, (2009) Lyme borreliosis: a European perspective on diagnosis and clinical management. Curr Opin Infect Dis 22: 450-454.
4. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, et al. (2006) The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 43: 1089-1134.
5. Bennet L, Danell S, Berglund J, (2003) Clinical outcome of erythema migrans after treatment with phenoxymethyl penicillin. Scand J Infect Dis 35: 129-131.
6. Smith RP, Schoen RT, Rahn DW, Sikand VK, Nowakowski J, et al. (2002) Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans. Ann Intern Med 136: 421-428.
7. Nowakowski J, Nadelman RB, Sell R, McKenna D, Cavaliere LF, et al. (2003) Long-term follow-up of patients with culture-confirmed Lyme disease. Am J Med 115: 91-96.
8. Wormser GP, Ramanathan R, Nowakowski J, McKenna D, Holmgren D, et al. (2003) Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 138: 697-704.
9. Vrethem M, Hellblom L, Widlund M, Ahl M, Danielsson O, et al. (2002) Chronic symptoms are common in patients with neuroborreliosis - a questionnaire follow-up study. Acta Neurol Scand 106: 205-208.
10. Ljostad U, Mygland A, (2009) Remaining complaints 1 year after treatment for acute Lyme neuroborreliosis; frequency, pattern and risk factors. Eur J Neurol.
11. Picha D, Moravcova L, Lasikova S, Holeckova D, Maresova V, (2006) Symptoms of post-Lyme syndrome in long-term outcome of patients with neuroborreliosis. Scand J Infect Dis 38: 747-748.
12. Henningsson AJ, Malmvall BE, Ernerudh J, Matussek A, Forsberg P, (2010) Neuroborreliosis-an epidemiological, clinical and healthcare cost study from an endemic area in the south-east of Sweden. Clin Microbiol Infect 16: 1245-1251.
13. Auwaerter PG, (2007) Point: antibiotic therapy is not the answer for patients with persisting symptoms attributable to lyme disease. Clin Infect Dis 45: 143-148.
14. Kowalski TJ, Tata S, Berth W, Mathiason MA, Agger WA, (2010) Antibiotic treatment duration and long-term outcomes of patients with early lyme disease from a lyme disease-hyperendemic area. Clin Infect Dis 50: 512-520.
15. Wormser GP, Schwartz I, (2009) Antibiotic treatment of animals infected with Borrelia burgdorferi. Clin Microbiol Rev 22: 387-395.
16. Ekerfelt C, Andersson M, Olausson A, Bergstrom S, Hultman P, (2007) Mercury exposure as a model for deviation of cytokine responses in experimental Lyme arthritis: HgCl2 treatment decreases T helper cell type 1-like responses and arthritis severity but delays eradication of Borrelia burgdorferi in C3H/HeN mice. Clin Exp Immunol 150: 189-197.
17. Kang I, Barthold SW, Persing DH, Bockenstedt LK, (1997) T-helper-cell cytokines in the early evolution of murine Lyme arthritis. Infect Immun 65: 3107-3111.
18. Wang WZ, Fredrikson S, Sun JB, Link H, (1995) Lyme neuroborreliosis: evidence for persistent up-regulation of Borrelia burgdorferi-reactive cells secreting interferon-gamma. Scand J Immunol 42: 694-700.
19. Widhe M, Jarefors S, Ekerfelt C, Vrethem M, Bergstrom S, et al. (2004) Borrelia-specific interferon-gamma and interleukin-4 secretion in cerebrospinal fluid and blood during Lyme borreliosis in humans: association with clinical outcome. J Infect Dis 189: 1881-1891.
20. Oksi J, Savolainen J, Pene J, Bousquet J, Laippala P, et al. (1996) Decreased interleukin-4 and increased gamma interferon production by peripheral blood mononuclear cells of patients with Lyme borreliosis. Infect Immun 64: 3620-3623.
21. Sjowall J, Carlsson A, Vaarala O, Bergstrom S, Ernerudh J, et al. (2005) Innate immune responses in Lyme borreliosis: enhanced tumour necrosis factor-alpha and interleukin-12 in asymptomatic individuals in response to live spirochetes. Clin Exp Immunol 141: 89-98.
22. Mullegger RR, McHugh G, Ruthazer R, Binder B, Kerl H, et al. (2000) Differential expression of cytokine mRNA in skin specimens from patients with erythema migrans or acrodermatitis chronica atrophicans. J Invest Dermatol 115: 1115-1123.
23. Jones KL, Muellegger RR, Means TK, Lee M, Glickstein LJ, et al. (2008) Higher mRNA levels of chemokines and cytokines associated with macrophage activation in erythema migrans skin lesions in patients from the United States than in patients from Austria with Lyme borreliosis. Clin Infect Dis 46: 85-92.
24. Borish L, (1998) IL-10: evolving concepts. J Allergy Clin Immunol 101: 293-297.
25. Ekerfelt C, Forsberg P, Svenvik M, Roberg M, Bergstrom S, et al. (1999) Asymptomatic Borrelia-seropositive individuals display the same incidence of Borrelia-specific interferon-gamma (IFN-gamma)-secreting cells in blood as patients with clinical Borrelia infection. Clin Exp Immunol 115: 498-502.
26. Grusell M, Widhe M, Ekerfelt C, (2002) Increased expression of the Th1-inducing cytokines interleukin-12 and interleukin-18 in cerebrospinal fluid but not in sera from patients with Lyme neuroborreliosis. J Neuroimmunol 131: 173-178.
27. Ekerfelt C, Ernerudh J, Bunikis J, Vrethem M, Aagesen J, et al. (1997) Compartmentalization of antigen specific cytokine responses to the central nervous system in CNS borreliosis: secretion of IFN-gamma predominates over IL-4 secretion in response to outer surface proteins of Lyme disease Borrelia spirochetes. J Neuroimmunol 79: 155-162.
28. Widhe M, Skogman BH, Jarefors S, Eknefelt M, Enestrom G, et al. (2005) Up-regulation of Borrelia-specific IL-4- and IFN-gamma-secreting cells in cerebrospinal fluid from children with Lyme neuroborreliosis. Int Immunol 17: 1283-1291.
29. Yin Z, Braun J, Neure L, Wu P, Eggens U, et al. (1997) T cell cytokine pattern in the joints of patients with Lyme arthritis and its regulation by cytokines and anticytokines. Arthritis Rheum 40: 69-79.
30. Gross DM, Steere AC, Huber BT, (1998) T helper 1 response is dominant and localized to the synovial fluid in patients with Lyme arthritis. J Immunol 160: 1022-1028.
31. Steere AC, Hutchinson GJ, Rahn DW, Sigal LH, Craft JE, et al. (1983) Treatment of the early manifestations of Lyme disease. Ann Intern Med 99: 22-26.
32. Luger SW, Paparone P, Wormser GP, Nadelman RB, Grunwaldt E, et al. (1995) Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother 39: 661-667.
33. Massarotti EM, Luger SW, Rahn DW, Messner RP, Wong JB, et al. (1992) Treatment of early Lyme disease. Am J Med 92: 396-403.
34. Lipsker D, Antoni-Bach N, Hansmann Y, Jaulhac B, (2002) Long-term prognosis of patients treated for erythema migrans in France. Br J Dermatol 146: 872-876.
35. Auvinen JP, Paananen MV, Tammelin TH, Taimela SP, Mutanen PO, et al. (2009) Musculoskeletal pain combinations in adolescents. Spine (Phila Pa 1976) 34: 1192-1197.
36. Hickie I, Davenport T, Wakefield D, Vollmer-Conna U, Cameron B, et al. (2006) Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ 333: 575.
37. Strle F, Nadelman RB, Cimperman J, Nowakowski J, Picken RN, et al. (1999) Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia. Ann Intern Med 130: 32-36.
38. Cerar T, Ruzic-Sabljic E, Glinsek U, Zore A, Strle F, (2008) Comparison of PCR methods and culture for the detection of Borrelia spp. in patients with erythema migrans. Clin Microbiol Infect 14: 653-658.
39. Ornstein K, Berglund J, Nilsson I, Norrby R, Bergstrom S, (2001) Characterization of Lyme borreliosis isolates from patients with erythema migrans and neuroborreliosis in southern Sweden. J Clin Microbiol 39: 1294-1298.
40. Lorenz E, Mira JP, Cornish KL, Arbour NC, Schwartz DA, (2000) A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 68: 6398-6401.
41. Bleharski JR, Li H, Meinken C, Graeber TG, Ochoa MT, et al. (2003) Use of genetic profiling in leprosy to discriminate clinical forms of the disease. Science 301: 1527-1530.
42. Andersson J, Abrams J, Bjork L, Funa K, Litton M, et al. (1994) Concomitant in vivo production of 19 different cytokines in human tonsils. Immunology 83: 16-24.
43. Comstedt P, Bergstrom S, Olsen B, Garpmo U, Marjavaara L, et al. (2006) Migratory passerine birds as reservoirs of Lyme borreliosis in Europe. Emerg Infect Dis 12: 1087-1095.